Coronary Artery Disease
Conditions
Keywords
Clopidogrel, Aspirin, Combination, Pharmacokinetics, Phase 1
Brief summary
The purpose of this study is to compare pharmacokinetics between fixed-dose combination and separate combination of clopidogrel 75mg/aspirin 100mg.
Interventions
Clopidogrel and Aspirin seperate combination, single dose
Fixed dose combination of clopidogrel/aspirin
Sponsors
Inje University
Chong Kun Dang Pharmaceutical
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* A healthy male volunteer aged 20 to 55, and within 20% of ideal body weight. * Have not any congenital or chronic diseases and medical symptom. * Appropriate subject for the study judging from examinations(interview, vital signs, 12-lead ECG, physical examination, blood, urinalysis result on screening. * Able to participate in the entire trial. * Signed the informed consent form prior to study participation.
Exclusion criteria
* Take metabolic enzyme inducing or inhibiting drugs like barbiturates within 28 days prior to the first IP administration. * show evidence of acute disease within 28 days prior to the first IP administration. * Have the medical history of bleeding symptom or bleeding disease * Have the disease history(ex. Inflammatory intestinal disease, stomach or duodenum ulcer, liver and bowels disease, appendectomy except of gastrointestinal surgery history) that may influence on the absorption, distribution, metabolism and excretion of the drug. * Have relevant hypersensitivity against drug or clinically significant allergic diseases except mild rhinitis that doesn't need medication. * Have hypersensitivity reaction histories for Clopidogrel or aspirin. * Have abnormal laboratory result. AST or ALT \> 1.25 times of upper limit/ Total bilirubin \> 1.5 times of upper limit/ PT, aPTT, BT over upper limit/ Platelet count \<150X10\^9/L or \>350X10\^9/L * A drug abuse or a heavy caffeine consumer (more than 5cups per a day) or a heavy smoker (more than 10 cigarettes per a day) or a regular alcohol consumer(more than 30g/day) or drinking within 7days prior to the first IP administration. * Have a diet(Especially, grapefruit juice-within 7days prior to the first IP administration) that may influence on the absorption, distribution, metabolism and excretion of the drug(s). * Have donated whole blood within 60 days prior to the first IP administration. * Participated in the other clinical trials within 90days prior to the first IP administration. * Take medicine which affect to this trial within 10 days prior to the first IP administration. * Appropriate subject for the trial judging from principal investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess the pharmacokinetic characteristics of clodiogrel/acetylsalicylic acid. | FDAAA) Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h | Assess Cmax, AUC, Tmax and t1/2(half-life) of clodiogrel/acetylsalicylic acid. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess the pharmacokinetic characteristics of salicylic acid. | Pre-dose, 0.33h, 0.67h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 6h, 8h, 10h, 12h, 24h | Assess Cmax, AUC, Tmax, t1/2(Half-life) of salicylic acid. |
Countries
South Korea
Outcome results
None listed